CareMed Has Been Selected as a National Specialty Pharmacy Provider for MYQORZO™ (aficamten) [Yahoo! Finance]
Cytokinetics, Incorporated (CYTK)
Last cytokinetics, incorporated earnings: 3/3 04:00 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.cytokinetics.com/investor-overview
Company Research
Source: Yahoo! Finance
Cytokinetics for MYQORZO™ ( aficamten ), indicated for the treatment of adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM) to improve functional capacity and symptoms. “MYQORZO represents a meaningful advancement for adults living with obstructive hypertrophic cardiomyopathy, and we are extremely excited to partner closely with the team at Cytokinetics to support patients and caregivers throughout their treatment journey,” said Benito Fernandez, Chief Commercial Officer. “CareMed's partnership with Cytokinetics reinforces our leading specialty pharmacy platform's strength and ability to support patients and caregivers suffering from rare and complex disease states.” MYQORZO is an allosteric and reversible inhibitor of cardiac myosin motor activity. In patients with HCM, myosin inhibition with MYQORZO reduces cardiac contractility and left ventricular outflow tract (LVOT) obstruction. MYQORZO was engineered to achieve a predictable exposure response, rapid onset
Show less
Read more
Impact Snapshot
Event Time:
CYTK
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CYTK alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CYTK alerts
High impacting Cytokinetics, Incorporated news events
Weekly update
A roundup of the hottest topics
CYTK
News
- Cytokinetics (NASDAQ:CYTK) had its "buy" rating reaffirmed by analysts at Jefferies Financial Group Inc..MarketBeat
- Cytokinetics (NASDAQ:CYTK) was given a new $90.00 price target on by analysts at Morgan Stanley.MarketBeat
- Important Notice to Long-Term Shareholders of Cytokinetics, Inc. (NASDAQ: CYTK); Lifecore Biomedical, Inc. (NASDAQ: LFCR); Molina Healthcare, Inc. (NYSE: MOH); and Synopsys, Inc. (NASDAQ: SNPS): Grabar Law Office Investigates Claims on Your BehalfGlobeNewswire
- Notice to Long-Term Shareholders of Cytokinetics, Inc. (NASDAQ: CYTK); Lifecore Biomedical, Inc. (NASDAQ: LFCR); Molina Healthcare, Inc. (NYSE: MOH); and WEBTOON Entertainment, Inc. (NASDAQ: WBTN): Grabar Law Office Investigates Claims on Your BehalfGlobeNewswire
- Cytokinetics to Present at the 44th Annual J.P. Morgan Healthcare ConferenceGlobeNewswire
CYTK
Earnings
- 11/5/25 - Miss
CYTK
Sec Filings
- 1/16/26 - Form 4
- 1/16/26 - Form 4
- 1/16/26 - Form 4
- CYTK's page on the SEC website